Pharmaceutical compsn. comprising cytokine

摘要

The use of a cytokine (I), or a combination of at least two (I), in systemically-administerable formulations for treatment of pre-neoplastic lesions is new. Pharmaceutical compsns. contg. (I) are also claimed. (I) is an interferon (INF) and/or tumour necrosis factor (TNF), each present at 100-100 million IU in the formulation. Pref. (I) are IFN gamma or TNF alpha, which can be isolated from natural cells or prepd. by genetic engineering methods. Doses esp. contain 0.01-10 million IU each (I), and are formulated conventionally with auxiliaries, stabilisers etc., e.g. albumin, electrolytes, injection solns., etc.